{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"23"}],"units":"Participants"}],"groups":[{"description":"Cohort 1: Participants received 25 mg Azacitidine sub-cutaneously, and 200 mg/m\\^2 Temozolomide orally; both once a day on Days 1 - 5 of a 28-day cycle.","id":"BG000","title":"Azacitidine 25 mg"},{"description":"Cohort 2: Participants received 50 mg Azacitidine sub-cutaneously, and 200 mg/m\\^2 Temozolomide orally; both once a day on Days 1 - 5 of a 28-day cycle.","id":"BG001","title":"Azacitidine 50 mg"},{"description":"Cohort 3: Participants received 75 mg Azacitidine sub-cutaneously, and 200 mg/m\\^2 Temozolomide orally; both once a day on Days 1 - 5 of a 28-day cycle.","id":"BG002","title":"Azacitidine 75 mg"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"23"}]}],"title":"≥ 18 years"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}],"title":"Female"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}],"title":"Male"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"23"}]}],"title":"Unknown"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex/Gender, Customized","unitOfMeasure":"Participants"}]}